A systematic review of cannabidiol dosing in clinical populations
A recent systematic review has revealed the need for dose-ranging clinical studies to provide a more definitive therapeutic range of cannabidiol (CBD). The review covered studies that showed clinical effectiveness for the treatment of epilepsy, anxiety, graft-versus-host disease, and a variety of others. CBD was found to be more effective at higher doses than lower doses in most cases, with few exceptions. Although CBD has been recognized to treat a slew of disorders phase III clinical trials that identify the most effective therapeutic range are severely lacking.
This study highlights the issue of dosing and why it has been so difficult to dose cannabis products. As cannabis is not recognized as having any medical value at the federal level it has been difficult to conduct research as there have been no federally funded studies. Cannabis contains a variety of cannabinoids and each cannabinoid would have to be tested separately and then in combination with each other, depending on the product, in order to elucidate dosing. The quicker cannabis is rescheduled by the federal government the quicker the pharmacy industry can supply definitive answers.
The study is available for review or download here:
View more studies like this in the CED Foundation Archive
To explore related information, click the keywords below: